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Anionic liposomes inhibit human immunodeficiency
virus type 1 (HIV-1) infectivity in CD4+ A3.01 and H9 cells
K. Konopka,1,2 B. R. Davis,3 C. E. Larsen 2 't and N.
Di.izgi.ine~ 1,2,4,*
1 Department of Microbiology, University of the Pacific,
School of Dentistry, San Francisco, CA 94115-2399,
USA.
2Cancer Research Institute, and "Depertment of
Pharmaceutical Chemistry, University of California; San
Francisco, CA 94143-0128, USA.
3Medical Research Institute, California Pacific Medical
Center, San Francisco, CA 94115, USA.

Summary
Immunodeficiency viruses undergo fusion with llposomes containing anionic phospholipids (Larsen et al.,
1990). We have investigated the effect of liposomes
composed of cardiolipin, phosphatidylserine or phosphatidylinositol, on the infectivity of three strains of
HIV-1 in A3.01 and H9 cells, measured by p24 (gag)
production in the medium. The infectiVity of HIV-1 in
A3.01 or H9 cells was inhibited by the presence of
cardiolipin Iiposomes during a 2h infection period,
with ICso's of 23.0, 4.8, and 5.0 ILM phospholipid,
respectively, for the different strains. Liposomes composed of phosphatidylserine or phosphatidylinositol
were ineffective under similar conditions. However,
prolonged pre-incubation of the virus with these llposomes also inhibited infectivity. Inhibition of virus
binding to cells could not account for the inhibition of
infectivity. We propose that the fusion products of
HIV-1 and anionic Iiposomes are impaired in their
ability to fuse with the plasma membrane.
Introduction
Human immunodeficiency virus type 1 (HIV-1) primarily
infects human T-Iymphocytes, monocytes and macrophages, and other cell types that express the CD4 antigen
. on the cell surface (Dalgleish et aI., 1984; Klatzmann et aI.,
1984; Gartner et al., 1985; Ho et aI., 1986). The CD4
protein also serves as the receptor for simian immunodeficiency virus (SIVmac) (Kannagi et aI., 1985). However,
Received 24 June, 1992; revised 6 September, 1992. tPresent address:
Department of Bioscience and Biotechnology, Drexel University, Philadelphia, PA 19104, USA. "For correspondence. Tel. 415-929-6565; Fax.
415-929-6654.

cells that do not express detectable amounts of CD4 can
also be infected with HIV-1 (Clapham et sl., 1989; Harouse
et al., 1989; Tateno et aI., 1989). Furthermore, expression
of the human CD4 molecule on the cell surface via
transfection may not be sufficient for HIV or SIV infection
(Maddon et aI.,1986; Clapham et al., 1991).
We have reported previously that HIV-1 and SIVmac can
fuse with phospholipid membranes (liposomes) lacking
the CD4 molecule (Konopka et aI., 1990; Larsen et al.,
1990, 1991). HIV-1 fuses both with negatively charged
cardiolipin (CL, 1,3-bisphosphatidyl-sn-glycerol) liposomes and with positively charged liposomes composed
of N-[2,3-(dioleyloxy)propyl]-N,N,N-trimethyl ammonium
chloride (DOTMA), but only very slowly with neutral
Iiposomes of
dioleoylphosphatidylcholine (DOPC)
(Konopka et aI., 1990, 1991). The fusion of HIV-1 with CL
Iiposomes is stimulated by reduced pH and the presence
of calcium (Larsen et al., 1990, 1991). Interestingly, the
fusion of cationic or anionic liposomess with HIV-1 affects
differentially the infectivity of the virus. Pre-incubation of
HIV-1 with DOTMAliposomes or the addition of such
Iiposomes during exposure of cells to the virus, enhances
the infectivity ofthe virus (Konopka et sl., 1990, 1991). The
enhancing effect of DOTMA liposomes on HIV-1 infectivity
is CD4-dependent, and appears to involve both virus-liposome fusion and liposome binding to the cell surface
(Konopka et aI., 1991). In contrast, preliminary results
indicated that pre-incubation of HIV-1 with CL liposomes
causes dose-dependent inhibition of HIV-1 replication in
CD4+ A3.01 cells, as measured by p24 (gag) antigen
production (Konopka et al., 1990, 1992). The mechanism(s) of the inhibitory effect of CL Iiposomes on HIV-1
infectivity is unclear. It is possible that both the ability to
fuse with the virus as well as the negative charge of
cardiolipin liposomes may contribute to the observed
inhibition. It is known that various negatively charged but
non-fusogenic compounds exert antiviral activity in vitro
against a variety of viruses, including HIV-1 (Takemoto
and Spicer, 1965; De Somer et aI., 1968; Saba et aI., 1988).
Here, we examined whether the presence of CL Iiposomes
during infection affected the infectivity of HIV-1 in two
CD4 + cell lines, and investigated the susceptibility of three
different isolates to this treatment. We focused on whether
CL Iiposomes affect the cell or the virus membrane. Since
pretreatment of A3.01 cells with cationic DOTMA Iiposomes enhances HIV-1 infectivity (Konopka et aI., 1991),
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Table 1. Effect of medium composition on the fusion rate of HIV-1 with
CL Iiposomes.
Reaction mixture

Serum content

Initial rate"

NaCllTES
NaCllTES {0.5mM Ca2+l
RPMI 1640 b
RPMI1640

None
None
None
10% FBS

25
73
41
1.3

a Initial fusion rates were calculated from the slopes of fluorescence
dequenching per unit time. Values are given as % Fmax min- 1.lnitial rates of
less than 5 were averaged over the first min (the rates of fusion in these
cases did not change appreciably with time). The others were averaged
over the first 0.2 min. Reaction medium conditions were set prior to
injection of CL liposomes {18.8fLMl. Virus concentration was 0.75 fL9
b The medium contained no phenol red.

mr'.

we investigated if the interaction of CL Iiposomes with
host cells affect HIV-1 infectivity. We determined whether
the effect of CL liposomes could be explained by its effect
on virus binding to cells. We also examined whether two
other negatively charged but less fusogenic liposomes,
phosphatidylserine (PS)and phosphatidylinositol (PI)(Larsen et al., 1991), could inhibit the infectivity of HIV-1.

obtained with HIV-1LAV, at 4 ng of viral p24 per 106 cells
(ICso of -20 fLM and -14 fLM, with p24 determinations after
7 and 10 days p.i., respectively; data not shown). CL
liposomes present during exposure of A3.01 cells to
HIV-1LAv-BRUIP reduced the infectivity of the virus to a
greater extent (ICso -4.8 fLM, with p24 determination after
7 days p.i.) than that of HIV-1LAV (Fig. 1B). Complete
inhibition of p24 production was achieved at concentrations of 25 to 100 fLM. CL liposomes, at concentrations of
1-100fLM and under such treatment conditions (2 x 107
cells mr': RPM1/10% FBS; 2h at 37°C), were not cytotoxic, as determined by trypan blue exclusion (data not
shown). The infectivity of purified HIV-1LAv-BRU, used for
the fusion experiments, was inhibited by CL Iiposomes to
a similar extent as that observed with propagated virus
(data not shown), although the overall production of p24 in
A3.01 cells infected with the purified virus, at 4ng of viral
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HIV-t fuses with cardiolipin liposomes
HIV-1 fuses rapidly with CL liposomes, as detected by the
dequenching of R18 due to dilution of the probe within the
fusion product. Fusion was also observed with both
freeze-fracture and negative-stain electron microscopy
(Larsen et al., 1991). Fusion of HIV-1 with CL liposomes
was dependent on the composition of the medium (fable
1). At pH 7.5, fusion was faster in the presence of RPMI
than in NaClfTES buffer alone. This may be due to the fact
that RPMI contains 0.45 mM Ca2 + (Larsen et al., 1991), but
the other constituents of the medium may also playa role.
Addition of 10% FBS significantly reduced, but did not
completely eliminate HIV-1 fusion with CL Iiposomes.
Thus, it is expected that the extent of fusion would reach
significant levels following a 2 h or 24 h pre-incubation of
the virus with CL liposomes in the presence of 10% FBS,
as described below.
HIV-t infectivity is inhibited by cardiolipin liposomes
present during the initial infection of A3.0t or H9 cells
When A3.01 cells were infected in the presence of CL
liposomes with HIV-1LAv, at 1Ong of viral p24 per 106 cells,
the production of p24 antigen in the culture supernatant
was inhibited with an ICso of -23 fLM (Fig. 1A). Over 90%
inhibition was observed at a lipid concentration of 100 fLM
(p24 = 0.64 ± 0.003 and 88.1 ± 15.1 ng rnr' compared to
9.9 ± 1.5 and 6390 ± 206.6ng ml" for untreated controls,
after 7 and 10 days p.i., respectively). Similar results were
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Fig. 1. Effect of CL liposomes on HIV-1 replication in A3.01 cells. CL
tlposornes were added during exposure of A3.01 cells to HIV-1 LAV at
10ng of viral p24 per 10 6 cells (at an Mal of 0.0016) (a) or HIVLAV-BRU/P at
4 ng of viral p24 per 106 cells (at an MOl of 0.018) (b) as described in the
text. Virus production was monitored by measuring HIV p24 in the
culture supernatant on 7 day post-infection as described in Materials
and Methods. Data represent the mean ± standard deviation of four
replicate p24 determinations on a single well or duplicate wells (control
infections).
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Table 2. Effect of CL Iiposomes present during infection on HIV-1 HTLV-JIIB replication in A3.01 and H9 cells.
A3.01 cells

H9 cells
10 days

7 days

mr ')

Treatment"

p24 (ng ml- 1) b

%c

p24 (ng

No Iiposomes
(control)
1 f1M CL
5f1M CL
10f1MCL
25f1M CL
5G-100 f1M CL

0.26 ± 0.05

100

1.25 ± 0.09

0.16 ± 0.07
0.12 ± 0.06
0.04 ± 0.04
0
0

61.5
46.1
15.4
0
0

0.69 ± 0.04
0.53 ± 0.09
0.27 ± 0.05
0
0

7 days

10 days

rnr')

%

p24 (ng ml- 1)

%

p24 (ng

100

0.23 ± 0.10

100

0.67 ± 0.20

55.2
42.4
21.6
0
0

0.11
0.12
0.05
0.04

±
±
±
±
0

0.02
0.01
0.04
0.02

47.8
52.2
21.7
17.4
0

0.18
0.14
0.05
0.04

±
±
±
±

0.01
0.01
0.02
0.01

0

%
100
26.9
21.0
7.5
6.0
0

"CL liposomes were added during exposure of A3.01 or H9 cells to virus at 4 or 6ng of viral p24 per 106 cells, respectively.
b p24 Antigen was determined in cell culture supernatant on 7 and 10 days post-infection. Data represent mean values ± S.D. (n = 4).
C Calculated as % of control infection (without liposomes).

.p24/1 06 cells, was approximately 10 times lower than
those infected with propagated HIV-1LAV-BRUIP (3.8 ± 0.1
VS. 34.4 ± 5.0ng p24 mr', respectively, on 7 day p.i.).
Similar reduction of the production of p24 (ICso ~5 /-LM)
was also observed when CL Iiposomes were present
during infection of A3.01 and H9 cells with HIV-1HTLV-IIIB
(Table 2). The ICso values were similar regardless of when
p24 production was measured (7,10,14, or 17 days p.i.)
(Table 2 and data not shown). The effect of CL liposomes
on HIV-1LAV infectivity of H9 cells was not tested.
The differential sensitivities ofthe three isolates of HIV-1
to the inhibitory effect of CL liposomes were not due to
their different infectivities measured as TCIDso. For
example HIV-1LAv-BRUIP and HIV-1HTLV-IIIB differed by
about 100-fold in TCIDso per 100 ng of viral p24 (4.6 x 10s
and 4.8 x 103 , respectively). However, CL liposomes
inhibited the infectivity of the two strains to a similar extent
(Fig. 1B and Table 2).
Presence of phosphatidylserine or phosphatidylinositol
Iiposomes during the initial infection of A3.01 cells does
not inhibit HIV-1 infectivity
To determine whether the inhibitory effect of CL llposornes
on HIV-1 infectivity was due to the negative charge of the
lipid, we tested the antiviral activity of two other negatively
charged, but less fusogenic, liposomes. The rate of fusion
of HIV-1 with negatively charged Iiposomes at neutral pH
depends on the lipid composition, and decreases in the
sequence pure CL > phosphatidylinositol (PI) > phosphatldylserine (PS) (Larsen et sl., 1991; and unpublished
results). When compared to pure CL Iiposomes the initial
rate of HIV-1 fusion with PI or PS Iiposomes was
decreased by about 9- and 19-fold, respectively, in
NaCl/TES buffer, pH 7.5, in the absence of Ca2 + , and by
about 1O-fold in the presence of 0.5 mMCa2 + (Larsen et al.,
1991). Addition of serum to the NaCl/TES buffer reduced
HIV-1 fusion with CL liposomes by 97% (Table 1). Thus, it

is expected that the interaction of PI or PS liposomes with
HIV-1 in the presence of 10% FBS would be very slow. In
contrast to CL lipsomes, the addition of PI or PS liposomes during infection, at concentrations between 10 and
100/-LM, did not affect p24 production in A3.01 cells (Fig.
2). The presence of PI or PS Iiposomes, at concentrations
of 5 and 50/-LM, also had no effect on HIV-1 infectivity in
A3.01 cells when the serum concentration was reduced to
0.2% during infection (data not shown). To compare
adequately the fusion of HIV-1 with different Iiposomes,
and the ability of these liposomes to inhibit infectivity, we
also examined the effect of liposomes on the infectivity of
the purified virus preparation used in the fusion studies.
Pre-incubation of HIV-1 with cardiolipin,
phosphatidylserine or phosphatidylinositolliposomes
reduces virus infectivity
Since HIV-1 could fuse with PS or Plliposomes and since
neither liposome type inhibited HIV-1 infectivity when
present during infection, we investigated whether preincubation of the virus with these liposomes affected
infectivity. HIV-1LAV-BRUIP was pre-incubated with CL, PS,
or PI liposomes, for either 2 h or 24 h at 37°C and then
incubated with A3.01 cells for 2h. The amount of HIV-1
p24 antigen released into culture supernatants (Table 3)
indicates that pre-incubation of HIV-1 with CL, PS, or PI
liposomes resulted in a dose- and time-dependent inhibition of virus replication. The inhibition of p24 production
in the supernatant of HIV-1-infected cells correlated with
the fusogenic activity of negatively charged Iiposomes in
NaCl/TES buffer alone. Both PS and PI liposomes had
some inhibitory effect at 5 /-LM. At a concentration of 50 /-LM,
PS Iiposomes, which fuse significantly slower with HIV-1
than CL or Plliposomes (Larsen et al., 1991), inhibited p24
production 3 days p.i. by 22% and 70%, after 2h and 24h
pre-incubation, respectively. Pre-incubation of HIV-1 with
50/-LM Plliposomes for 2 h or 24 h reduced the infectivity of
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the virus by 46% and 100%, respectively. Under the same
conditions, 5 and 50/-LM CL Iiposomes inhibited viral
replication by 99% and 100%, respectively, after a 2h
pre-incubation, and by 100% after a 24h pre-incubation.
Similar results wre obtained after 7 days post-infection
(Table 3).
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Fig. 2. Effect of CL. PS, and PI Iiposomes on HIV-1 LAV (a) and purified
HIV-1 LAV-BRU (b) replication in A3.01 cells. CL. PS, and PI Iiposomes
were added during exposure of A3.01 cells to virus (4ng of viral p24 per
106 cells) as described in the text. Virus production was monitored by
measuring HIV p24 in the culture supernatant on 7 day post-infection as
described in 'Materials and Experimental procedures'. Data represent
the mean ± standard deviation of four replicate p24 determinations on a
single well or duplicate wells (controls infections).

To determine whether the inhibitory effect of CL Iiposomes
was due to binding to sites on the cell surface, A3.01 cells
were pre-incubated with various concentrations of CL
liposomes (10 to 100 /-LM lipid), both in the presence of
10% FBS and without serum. The cells were then washed
and exposed to HIV-1LAV at 4ng viral p24/10 6 cells, as
described in Methods, and cultured for 7 days. Under such
treatment conditions CL liposomes showed no cytotoxicity to the cells in the presence of serum (data not shown).
However, in the absence of serum cytotoxicity of CL
liposomes was observed with a CDso of -25/-LM. Pretreatment of A3.01 cells with CL Iiposomes in the presence
of 10% FBS did not affect p24 production when compared
to untreated cells. For example, when A3.01 cells were
pre-treated with 50 or 100 /-LM CL liposomes, the values of
p24 determined in the supernatant after 7 days were 2.75
± 0.21 and 2.35 ± 0.28ng mr', respectively, while for
cells treated with RPM) medium alone (control) this value
was 2.78 ± 0.59 ng rnr' (the mean ± standard deviation.n
= 4).
Inhibition of infectivity by cardiolipin liposomes is not
due only to decreased virus binding to cells

We investigated whether decreased infectivity in the
presence of CL Iiposomes was due to inhibition of virus

Table 3. Effect of preincubation of HIV-1 LAV-BRU/P with CL, PI, and PS Iiposomes on HIV-1 infection of A3.01 cells.
3 days p.i.
24 h pre-incubation

2 h pre-incubation
Treatment"
No Iiposomes
(control)
5floMCL
50floM CL
5floM PI
50floM PI
5floM PS
50floM PS

p24 (ng ml- 1)b
5.2 ± 0.7
0.06 ±
0
4.5 ±
2.8 ±
4.3 ±
4.0 ±

0.0004
0.4
0.1
0.2
0.3

7 days p.i.

rnr')

%c

p24 (ng

100

0.37 ± 0.13

1.2
0
86.5
53.8
82.7
76.9

0
0
0.31 ± 0.02
0
0.37 ± 0.02
0.11 ± 0.01

2 h pre-incubation

%

p24 (ng

rnr')

%c

100

260.1 ± 64.1

100

0
0
83.8
0
100
29.7

6.0 ±
0
218.8 ±
120.4 ±
209.0 ±
92.0 ±

0.4
15.5
19.1
19.0
8.7

9.9
0
84.1
46.3
80.4
35.4

24 h pre-incubation
p24 (ng rnl')
9.1 ± 0.4
0
0
13.1 ± 1.3
0.66 ± 0.05
12.7 ± 0.8
4.9 ± 0.3

%
100
0
0
143
7.2
139
53.7

HIV-1 LAV BRUIP was pre-incubated without or with CL, PI, or PS liposomes for 2 h or 24 h at 37°C. A3.01 cells were infected with pre-incubated HIV-1 LAV-BRUIP
(4ng of viral p24 per 106 cells).
b p24 Antigen was determined in cell culture supernatant 3 and 7 days post-infection. Data represent the mean ± standard deviation of four replicate p24
determinations on a single well or duplicate wells (control infections).
C Calculated as % of control infection (pre-incubation of virus without Iiposomes).
a

,r ...
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binding to cells. Binding was measured at O°C since HIV-1
is not expected to fuse at this temperature (Sinangil et aI.,
1988; Orloff et al., 1991). A3.01 cells were exposed to the
virus at O°C, in the absence or presence of CL Iiposomes.
The Iiposomes and free virus were then removed by
washing the cells. The presence of CL Iiposomes, at
concentrations of 5-50 [LM, reduced binding of HIV-1 by
29% and 32%, respectively (Fig.3a).This bound virus was
allowed to infect the cells by raising the temperature to
3YOC and virus production in the supernatant was
determined 3 days p.i. (Fig. 3B). Similar results were
obtained after 5 days p.i. (data not shown). At 50 [LM CL the
amount of p24 was reduced to 3% of that produced by
control cells treated identically except for the absence of
liposomes. In a separate experiment 50 [LM CL reduced
binding by 56% while inhibiting infectivity by 88% (12% of
p24 production in controls). Thus, infectivity was inhibited
to a greater extent than binding.
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Our results indicate that CL liposomes are inhibitory to
HIV-1 infection of two CD4+ T-cell lines, A3.01 and H9.
Similar results were obtained with a human monocytic
leukaemia cell line, THP-1 (unpublished observations).
The inhibitory effect of CL liposomes on HIV-1 infectivity
does not appear to be merely due to the negative charge of
the lipid, since two other negatively charged liposomes
composed of PI or PS affected HIV-1 infectivity only after
prolonged pre-incubation with the virus. Although the
initial rate of fusion between HIV-1 and CL Iiposomes was
reduced after addition of serum to RPMI medium (fable 1),
virus and Iiposomes can fuse with each other to a
significant extent during a 2 h incubation. One reason for
the lack of anti-HIV-1 activity of PI and PS liposomes
present during the infection period may be their lower
fusion activity compared to CL liposomes. Although all
these lipids carry 1 net negative charge per 2 acyl chains,
the molecular arrangements and nature of the charged
groups are different. PS has carboxy, phosphate and
amino groups connected to 2 acyl chains, while CL has
two phosphate groups connected to 4 acyl chains via a
glycerol backbone, and PI contains a phosphate moiety
shielded by the inositol residue.
Earlier reports have indicated that various negatively
charged compounds exert antiviral activity against a
variety of viruses in vitro (Takemoto and Spicer, 1965; De
Somer et aI., 1968; Baba et aI., 1988) but the exact
mechanism(s) of their inhibitory effect remains obscure.
Sulphonated compounds such as suramin (bis-naphthalenetrisulphonic acid), suramin analogues, and Evans
blue inhibit HIV replication (Balzarini et al., 1986a, 1986b;
Mohan et al., 1991). Aurin tricarboxylic acid is thought to
inhibit HIV adsorption to host cells by binding to lysine
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Fig. 3. Effect of CL Iiposomes on HIV-1 binding and infectivity. CL
liposomes were added during exosure of A3.01 cells to HIV-1 LAV.BRUIP at
100 ng of viral p24 per 106 cells (at an Mal of 0.46) as described in the
text. Virus binding was monitored by measuring HIV p24 in the cell
Iysates (a) and virus replication was measured by p24 production in cell
culture supernatants on 3 day post-infection (b) as described in
'Materials and Experimental procedures'. Data represent the mean ±
standard deviation of two replicate p24 determinations in duplicate (n =
4).

and/or arginine residues on CD4 involved in gp120 binding
(Schols et aI., 1989). Sulphated polysaccharides (dextran
sulphate, pentosan polysulphate, heparin) and modified,
negatively charged, human serum albumins appear to
inhibit HIV infection by interfering with virus attachment
and fusion (Baba et al., 1988; Mitsuya et et., 1988; Jansen
et al., 1991). Recently, it was proposed that dextran
sulphate interacts with positively charged amino acids
concentrated in the V3 region of gp120 (Callahan et al.,
1991). It is possible that interactions with this region are
also responsible for the observed inhibitory effect of CL
Iiposomes. Negatively charged molecules can also affect
cell surface CD4. Gangliosides, negatively charged glycolipids containing sialic acids, are known to down-modulate surface CD4 (Offner et al., 1987) and the CD4/Thy-1
fusion protein, which is anchored to the membrane by a
glycosylphosphatidylinositol tail (Jasin et al., 1991).
Sulphation of gangliosides enhances their inhibitory effect
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compared to unsulphated analogues even in the presence
of 10% FBS (Handa et aI., 1991). Liposomes containing
sulphated galactocerebroside (sulphatide) or cholesterol
sulphate also inhibit syncytium formation induced by
bovine immunodeficiency virus (BIV) infected cells (Watari
et aI., 1990). The inhibitory effect of sulphatide alone, not
incorporated into liposomes, is low and the fusion of
liposomes containing sulphated lipids with the membranes of BIV-infected and/or -uninfected cells has been
suggested as an important step in the antiviral activity
(Watari et aI., 1990).
CL liposomes inhibited the original step of infection,
HIV-1 binding to the cell surface, to a certain extent.
However, this level of inhibition (43%) could not account
for the extent of inhibition of the subsequent infection
(97%). The ability of the fusion product to fuse with fresh
CL Iiposomes is indeed diminished, as demonstrated by
R18 fluorescence dequenching experiments (C. E. Larsen
et aI., personal communication). Future studies will examine whether CL liposomes inhibit the initial fusion step, by
assaying virus-cell membrane lipid mixing and the
intracellular delivery of p24, and monitoring the reverse
transcription step by means of PCR analysis.
Our studies indicate that the antiviral effects of CL
liposomes vary quantitatively among different strains of
HIV-1 propagated in different cell lines. These findings
were not unexpected, since strain specific antiviral effects
of dextran sulphate (Busso and Resnick, 1990; Schols et
al., 1992) and rsCD4 (Daar et al., 1990) have also been
reported. Passage of HIV-1 isolates through various
human cell lines can alter the cellular host range tropism
(Cheng-Mayer et al., 1991; Peden et al., 1991), because of
differences in the cell-type-dependent glycosylation of the
same viral envelope protein (Cheng-Mayer et al., 1991). It
has been also suggested that the genotypes of some
viruses in vitro are not stable and that selection for growth
causes the appearance of variants with increased growth
potential and expanded host range in the absence of
immune selection of the host (Peden et aI., 1991). Therefore, it will be of interest to examine the effect of anionic
Iiposomes on the infectivity of well characterized isolates
that differ extensively with respect to sequence and
biological properties.
Our observations with CL liposomes raise the possibility
of using such liposomes for therapeutic purposes. The
concentrations of liposomes necessary tor complete
inhibition of infectivity are up to 1OO-fold lower than those
injectable intravenously into experimental animals. Moreover, liposornes with long circulation times have been
developed recently (Gabizon and Papahadjopoulos,
1988). It will be of interest to examine whether similar
Iiposomes containing relatively low mole fractions of CL
will inhibit infectivity and retain their ability to circulate for
long periods in serum. HIV infectivity may not only be

inhibited by Iiposomes themselves but also by encapsulated antiviral drugs which can enter the virus interior via
fusion. Additionally, the covalent coupling of rsCD4 to the
Iiposomes may render the Iiposomes highly specific for
binding to and fusion with HIV-1 or HIV-infected cells
(DOzgOne§ et al., 1992). These studies are in progress in
our laboratory.

Materials and Experimental procedures
Compounds
Phospholipids (CL, PI, PS)were obtained from Avanti Polar Lipids
(Alabaster, AL). Octadecylrhodamine (R18) was purchased from
Molecular Probes, Inc. (Eugene,OR).Octaethyleneglycol dodecyl
ether (C12E8 ) detergent was from Calbiochem, Inc. (La Jolla, CAl.

Cell lines
The CD4+ human Iymphoblastoid cell line, A3.01, was obtained
from T. Folks, and the H9 cell line was obtained from R. C. Gallo,
through the AIDS Research and Reference Reagent Programme
(Division of AIDS, NIAID, NIH, Bethesda, MD). H9/HTLV-IIIB cells
were kindly provided by J. Mills (San Francisco General Hospital).
The cells were maintained in RPMI 1640 medium (Irvine Scientific,
Santa Ana, CAl supplemented with 10% (vlv) heat-inactivated
fetal bovine serum (FBS) (Irvine Scientific), penicillin (50 units
mr '), streptomycin (50 fL9 mr '), and L-glutamine (2mM)at 37"C.
The cells were split 1:6 and fresh medium was added every 3-4
days.

Fusion experiments
To determine the fusion of HIV-1 with llposornes, the virus
(LAV-BRU, now designated as LAV-LAI [Wain-Hobson et al.,
1991] [Pasteur Institute, Paris, France]) was propagated in human
Iymphoblastoid leukaemia (CEM) cells, purified as described
(Larsen et al., 1990) and stored at - 70°C. This preparation was
provided by M. Jennings (Department of Medical Pathology, UC
Davis). Purified HIV-1 LAV-BRU contained all viral antigens, including gp41 and gp120 (detected by Western blot), and was
infectious as determined by its ability to induce syncytia formation
and cell-free p24 antigen production in A3.01 cells. HIV-1 LAV-BRU
(100fL9) was labelled with octadecylrhodamine (R18 ) at 3 mole%
of the total viral lipid, by incubating the virus with an ethanolic
solution of the fluorophore (final [ethanol] <1 %) for 1 h at room
temperature (Hoekstra et al., 1984; Larsen et al., 1990). It was
necessary to use purified virus for these experiments to avoid
labelling of other membranous material or serum components in
cell culture supernatant. Free fluorophore was not present (an
excess of added unlabelled virus did not result in redistribution of
R18 ; labelled virus chromatographed on Sephadex G-50 to
eliminate any free R18 gave similar results). R18-labelled HIV-1
remained infectious as determined by the methods above. The
dilution of R18 into target membranes was measured by following
the increase of rhodamine fluorescence, which results from the
relief of self-quenching upon membrane fusion (Hoekstra et el.,
1984). Fluorescence measurements were performed with a
Perkin-Elmer LS-5B fluorometer, as described earlier (Larsen et
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el., 1990). Maximal fluorescence (Fmax = 100%) was set by lysing
the virus and Iiposome suspension with C1 2E s (final concentration: 0.1-0.5% [wlv]), which completely disperses the fluorophore.

Virus stocks
The lJ>...V strain of HIV-1, designated as HIV-1LAV, was obtained
from Dr T. M. Folks and propagated in A3.01 cells. The purified
HIV-1 (labelled as HIV-1LAv-BRu) was also propagated in A3.01
cells, and the propagated virus was designated as HIV-1LAV-BRUlp.
The supernatant of chronically infected H9/HTLV-IIIB cells was
used as a source of the HIV-1 strain, HTLV-IIIB. The culture
supernatants were harvested at times of peak p24 production,
filtered through Millipore filters of 0.22 urn pore diameter, and
stored in 1-ml aliquots at -80°C. The reverse transcriptase
activity of the virus stock solutions was 8.8 x 105,2.5 X 106 , and
3.9 x 106 c.p.m. mr ' and the eusx-reactlve p24 protein yielded
1.0, 2.6, and 0.3f1g rnl" for HIV-1LAv, HIV-1LAv-BRu/P and
HIV-1HTLV-IIIB, respectively.
The tissue culture infectious dose, 50% endpoint (TCID5 0 ) , was
determined by inoculating replicate microtitre wells of A3.01 or H9
cells (2 x 104 cells well- 1) in 96-well flat-bottom plates (Corning)
with serial dilutions of cell-free supernatants (Johnson and
Byington, 1990). Each well was scored daily for evidence of
virus-induced cytopathic effect (CPE) (the presence of syncytia,
ballooning cytoplasm, etc.). The cells were split 1:2 twice weekly
and fed with fresh medium, until peak infection was noted, usually
after 9 or 10 days. The infectious titre per 100 ng p24 antigen was:
HIV-1LAv, 1.64 x 104 TCID5 0 ; HIV-1LAv-BRUlP, 4.6 x 105 TCID5 0
(both on A3.01 and H9 cells); and HIV71 HTLV-IIIB, 4.8 x 103TCID 5o ,
on H9 cells. Viral inocula were standardized by their p24 content,
and cultures were infected at a concentration of p24 between 4
and 10ng p24 per 106 cells, as described in the Figure and Table
legends. Viral p24 antigen was determined in cell-free supernatant by the HIV-1 p24 antigen capture assay described previously
(Konopka et et., 1990).

Preparation of liposomes
Liposomes were prepared in 150 mMNaCI, 10 mM N-(Tris[hydroxymethyllmethyl)-2-aminoethane sulphonic acid (TES), pH 7.5,
either by reverse phase evaporation (Szoka et a/., 1980) or by
hydrating dried lipid (Bangham et a/., 1965), and extruded three
times under argon, through double polycarbonate membranes of
0.0811-m pore diameter in a Lipex Biomembranes (Vancouver, BC)
high pressure extrusion apparatus, to achieve a uniform size
distribution (Szoka et a/., 1980). This procedure results in the
production of predominantly unilamellar vesicles (DOzgOnel? et
aI., 1983; Hope et a/., 1985). The lipid concentration was
determined by phosphate assay (Bartlett, 1959).

HIV infection of cells
Cells (2 x 107 rnr') were exposed to HIV-1 for2hat37"C, washed
three times to remove unbound virus, resuspended at 5 x 10 5
cells mr ' in RPMI-1640/1 0% FBS and cultured at 37°C in 12-well
culture plates (4ml per well). Control cells were treated similarly
but not exposed to the virus. Every 3 or 4 days, 3ml of the
supernatant was removed and fresh medium was added. Following incubation for various time periods (e.g. 3, 7, 10 days), the
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number of viable cells was determined by Trypan Blue exclusion,
and p24 antigen in the harvested samples of cell-free supernatant
was measured by ELISA (Konopka et el., 1990).
The effect of Iiposomes on HIV-1 infectivity was investigated
using three different protocols: (1) the cell-free virus was pretreated with Iiposomes before addition to the cells, (2) Iiposomes
were added to the culture medium during exposure of cells to
virus, or (3) the cells were pre-treated with Iiposomes before
addition of virus.
HIV-1LAv-BRUlP (O.4l1-g viral p24
was pre-incubated with
various concentrations of Iiposomes for 2h or 24h at 37"C and
then diluted with a cell suspension to give 4ng of viral p2410- 6
cells. Control virus was pre-incubated without Iiposomes.
A3.01 cells (2 x 107 cells mr ') were pre-incubated with various
concentrations of CL liposomes for 1 h at 37°C, washed three
times to remove unbound CL and then exposed to HIV-1LAV at
4 ng of viral p24 10-6 cells. After virus adsorption for 2 h at 37"C,
the cells were washed three times, resuspended at 5 x 105 cells
ml" and cultured in 12-well culture plates. Following incubation,
cell viability was assessed visually both with and without the use
of Trypan Blue, and p24 antigen was measured in duplicate in the
supernatant.

mr')

Quantitation of HIV-1 binding to A3.01 cells
HIV-1LAV-BRu/P was added to A3.01 cells at 200ng of viral p24 per
2 x 106 cells in 0.2 rnl, at a multiplicity of infection (MOl) of 0.46
infectious virus/target cell. The virus-cell mixture, in the absence
or presence of CL Iiposomes, was maintained at O°C for 60 min to
allow binding without internalization. The cells were washed to
remove unbound virus and divided into two portions, each
containing 1 x 106 cells. The first portion of cells was lysed with
1% Triton X-100. The lysate, representing cell-bound and/or
cell-internalized viral antigen, was centrifuged at 13000 x g for 10
min and p24 antigen was measured in the supernatant. The
second portion was resuspended at 5 x 105 cells ml- 1 and
cultured in 24-well culture plates (2ml well- 1) at 37"C, and on days
3 and 5 of culture, 1 ml of the supernatant was removed and fresh
medium was added. The harvested samples of cell-free supernatant were tested for p24 antigen.
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